Onkologie. 2017:11(2):78-82 | DOI: 10.36290/xon.2017.016

Systemic therapy in the treatment of uterine cervix carcinoma

Igor Sirák, Miroslav Hodek, Zdeněk Zoul
Klinika onkologie a radioterapie, Fakultní nemocnice Hradec Králové

Comprehensive treatment of cervical carcinoma patients necessarily requires interdisciplinary cooperation. Early stage disease is

radically solved by adequate surgical intervention. Locally or regionally advanced disease is treated by definitive chemoradiation with

curative intent. Surgery and radiotherapy may be utilized effectively in the palliative treatment of recurrent, persistent, or metastatic

disease. Systemic treatment has its use across most stages of this malignancy, whether in the neoadjuvant, concomitant, or palliative

setting. The aim of this article is to provide the review of systemic therapy utilization in the treatment of uterine cervix carcinoma.

Keywords: uterine cervix carcinoma, systemic treatment, chemotherapy, cisplatin, bevacizumab

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sirák I, Hodek M, Zoul Z. Systemic therapy in the treatment of uterine cervix carcinoma. Onkologie. 2017;11(2):78-82. doi: 10.36290/xon.2017.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kim HS, Sardi JE, Katsumata N, et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 2013; 39: 115-124. Go to original source... Go to PubMed...
    2. Gong L, Lou JY, Wang P, et al. Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer. Int J Gynaecol Obstet 2012; 117: 23-26. Go to original source... Go to PubMed...
    3. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of (bulky) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol 2007; 106: 362-369. Go to original source... Go to PubMed...
    4. Rydzewska L, Tierney J, Vale CL, Symonds PR. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2010. Go to original source... Go to PubMed...
    5. Robova H, Rob L, Halaska MJ, et al. High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer. Gynecol Oncol 2013; 128: 49-53. Go to original source... Go to PubMed...
    6. Green JA, Kirwan JM, Tierney JF, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358(9284): 781-786. Go to original source... Go to PubMed...
    7. Lukka H, Hirte H, Fyles A, et al. Concurrent Cisplatin-based Chemotherapy plus Radiotherapy for Cervical Cancer - a Meta-analysis. Clinical Oncology 2002; 14: 203-212. Go to original source... Go to PubMed...
    8. Sirák I, Petera J, Odrážka K, et al. Význam intenzity chemoterapie v konkomitantní chemoradioterapii lokálně pokročilého karcinomu čípku děložního. Česká gynekologie 2006; 4: 308-311.
    9. Sirák I, Petera J, Zoul Z. The Influence of Cisplatin Dose upon Survival in Concurrent Chemoradiotherapy of Locally Advanced Cervical Carcinoma with Weekly Cisplatin. Acta Medica 2008; 51(2): 95-99. Go to original source... Go to PubMed...
    10. Sirák I, Kašaová L, Vošmik M, et al. Technika IMRT v léčbě gynekologických malignit. Čes gynek 2010; 75(3): 177-181.
    11. Mell LK, Sirák I, Wei L, et. al. Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IV cervical cancer: An international multi-center phase II clinical trial (Intertecc-2). Int J Radiat Oncol Biol Phys 2017; 97(3): 536-545. Go to original source... Go to PubMed...
    12. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18(8): 1606-1613. Go to original source... Go to PubMed...
    13. Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003; 9: 425-432. Go to original source... Go to PubMed...
    14. Bonomi P, Blessing JA, DiSaia PJ, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology study. J clin Oncol 1985; 3: 1079-1085. 833-835. Go to original source... Go to PubMed...
    15. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989; 32: 198-202. Go to original source... Go to PubMed...
    16. Omura GA, Blessing JA Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifofamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1997; 17: 165-171. Go to original source... Go to PubMed...
    17. Bloss JD, Blessing JA, Behrens BC, et al. Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2002; 20: 1832-1837. Go to original source... Go to PubMed...
    18. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3113-3119. Go to original source... Go to PubMed...
    19. Long HJ, Bundy BN, Grendys EC, Jr., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-4633. Go to original source... Go to PubMed...
    20. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2009; 27: 4649-4655. Go to original source... Go to PubMed...
    21. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007; 105: 299-303. Go to original source... Go to PubMed...
    22. Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505) [abstract]. J Clin Oncol 2012; 30(Suppl. 15): Abstract 5006. Go to original source... Go to PubMed...
    23. Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370(8): 734-743. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.